🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

19 recruiting trials

for Neuroendocrine Carcinomas (NEC)

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC NCT07416695Phase 12 sites📍 Beijing📍 Shanghai Shanghai Henlius Biotech · Tests: HLX3901 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma NCT06157827Phase 1, Phase 225 sites📍 Hefei📍 Hefei📍 Beijing Nanjing Leads Biolabs Co.,Ltd · Tests: LBL-024 for Injection, Etoposide Injection, Carboplatin Injection, Atezolizumab injection, Cisplatin injection Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors NCT07278479Phase 1, Phase 28 sites📍 Tampa📍 Atlanta📍 Chicago Molecular Partners AG · Tests: [212Pb]Pb-MP0712, [203Pb]Pb-MP0712 Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites📍 Iowa City📍 Boston📍 Royal Oak Novartis Pharmaceuticals · Tests: 225Ac-ETN029, 111In-ETN029 A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity NCT06406465Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Belinostat, Cisplatin, Etoposide ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma NCT07038096Phase 1, Phase 21 site📍 Guanzhou Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZG006, ZG005 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection NCT06503146Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: [18F]FAPI-74, [18F]FDG Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients NCT06893783Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Inkeun Park · Tests: Tarlatamab A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) NCT07488923Phase 17 sites📍 St Louis📍 Hackensack📍 New York Moonlight Bio, Inc · Tests: ML261 A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer NCT07174583Phase 1, Phase 213 sites📍 Denver📍 Orlando📍 Fort Wayne IDEAYA Biosciences · Tests: IDE849, durvalumab, IDE161, Carboplatin A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686Phase 1, Phase 215 sites📍 Duarte📍 Los Angeles📍 Denver Phanes Therapeutics · Tests: Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma NCT07518602Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Chidamide, Sintilimab, Bevacizumab SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) NCT06889493Phase 11 site📍 Miami Peter Hosein, MD · Tests: Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease NCT07509034Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) NCT07016230Phase 23 sites📍 Bordeaux📍 Nice📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: Tarlatamab FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum NCT06393816Phase 231 sites📍 Aix-en-Provence📍 Amiens📍 Angers Centre Leon Berard · Tests: Durvalumab with etoposide and Carboplatin/Cisplatin Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung NCT05058651Phase 2, Phase 3265 sites📍 Anchorage📍 Phoenix📍 Phoenix National Cancer Institute (NCI) · Tests: Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy